Bone destruction

Bone destruction, also known as osteolysis, is a pathological process characterized by the excessive and disproportionate resorption of bone tissue, primarily mediated by overactive osteoclasts. Under physiological conditions, bone remodeling is a tightly regulated balance between bone resorption by osteoclasts and bone formation by osteoblasts; however, in various disease states, this balance is disrupted in favor of resorption (StatPearls, 2023). This process is frequently observed in clinical conditions such as osteoporosis, rheumatoid arthritis, Paget's disease, and bone metastases from solid tumors or hematologic malignancies like multiple myeloma (NIH, 2022). The primary molecular drivers include the RANK/RANKL/OPG signaling pathway, where an excess of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) promotes osteoclast differentiation and survival. Therapeutic strategies aimed at halting bone destruction include the use of bisphosphonates, which induce osteoclast apoptosis, and monoclonal antibodies like Denosumab, which neutralize RANKL (PubMed, 2021). Monitoring this process often involves assessing bone turnover markers such as C-terminal telopeptide (CTX) to evaluate drug efficacy and disease progression.

Other names

OsteolysisBone resorptionBone erosionPathological bone lossOsteoclastic bone resorption

Inhibition of osteoclast-mediated bone resorption via various mechanisms: RANKL neutralization (Denosumab), induction of osteoclast apoptosis and inhibition of farnesyl pyrophosphate synthase (Bisphosphonates), inhibition of Cathepsin K (Odanacatib), or antagonism of sclerostin to promote bone formation (Romosozumab).